Quantum BioPharma Ltd. has implemented two significant corporate actions to optimize its financial structure and support its strategic objectives. The company granted 60,000 restricted share units (RSUs) under its equity incentive plan, which are contingent upon specific vesting criteria.
In a parallel move, the company's board of directors authorized the settlement of outstanding debt to arm's length parties by issuing Class B Shares. These shares will be issued at a deemed price of US$6.75 per share, representing a strategic approach to managing the company's financial obligations.
These corporate actions underscore Quantum BioPharma's commitment to maintaining financial flexibility while continuing to advance its portfolio of innovative biotech solutions. The company focuses on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders.
Through its subsidiary Lucid Psycheceuticals Inc., the company is particularly focused on developing Lucid-MS, a patented compound aimed at preventing and reversing myelin degradation in multiple sclerosis preclinical models. Additionally, the company retains a 25.71% ownership stake in Celly Nutrition Corp. and maintains a royalty structure for the UNBUZZD product.
These strategic moves demonstrate Quantum BioPharma's ongoing efforts to manage corporate resources, incentivize key personnel through equity grants, and maintain a robust investment portfolio across various biotech initiatives.
